MarketResearchReportStore adds "Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016" latest studies, published in March 2017. It is a professional and in-depth study on the current state.

For a sample of this report, please email at: [email protected]

Description
Summary
‘Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope
- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
- The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Request Sample Copy, please email at: [email protected]

Table Of Contents
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Overview 6
Therapeutics Development 7
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Stage of Development 7
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Therapy Area 8
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Indication 9
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Companies 12
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development 20
Aviara Pharmaceuticals Inc 20
Encycle Therapeutics 21
Genentech Inc 22
Protagonist Therapeutics Inc 23
Takeda Pharmaceutical Company Ltd 24
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles 25
etrolizumab - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
PTG-100 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile 29
Product Description 29

Browse Complete Report with TOC @
https://www.marketresearchreportstore.com/shop/integrin-beta-7-gut-homing-receptor-beta-subunit-or-itgb7-pipeline-review-h2-2016

For report sample or more information, please feel free to contact us:
Shirley | Sales Director
Call: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/

About Us
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best.